Sharekhan

Supriya Lifescience Ltd

Thu 11/09/2025,11:54:57 NSE: SUPRIYA

₹ 656.75 2.20 (0.34%)
BUY NOW Buy Supriya Lifescience Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Supriya Lifescience Ltd

Thu 11/09/2025,12:8:0

Supriya Lifescience Ltd

Thu 11/09/2025,11:54:57 | NSE : SUPRIYA

₹ 656.752.20 (0.34%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 661.00

Previous Close

₹ 654.55

Volume

36750

Mkt Cap ( Rs. Cr)

₹5285.71

High

₹ 670.00

Low

₹ 655.50

52 Week High

₹ 842.00

52 Week Low

₹ 511.40

Book Value Per Share

₹ 112.56

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Supriya Lifescience Ltd

Your Vote -

Buy

65.91%

Hold

5.68%

Sell

28.41%

65.91%

88 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

40%

Sell Order Quantity

60%

Bid Price

Qty

657.25

20

657.00

16

657.00

20

657.00

14

657.00

10

Bid Total

23389

Bid Price

Qty

658.00

9

658.00

3

658.00

19

658.00

5

658.00

1

Bid Total

35572

Option Chain

Analyzes market sentiment, predicts Supriya Lifescience Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Supriya Lifescience has declared 50% Final dividend for the financial year March 2025

    3 Sep 2025, 6:40PM Supriya Lifescience Ltd. on Tuesday, 27 May 2025, has announced Final dividend of 50 percent on Equity Share, to its shareholders holding shares on th

  • Supriya Lifescience - Copy of Newspaper Publication

    2 Sep 2025, 2:34PM Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication regarding intimation of Dispatch of Annual Report, AGM Notic

  • Supriya Lifescience - Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The Company Providing

    2 Sep 2025, 2:25PM Enclosed herewith is the Letter dispatched by the Company to the Shareholders whose email ids are not registered with the Company / Depositories / RTA

  • Supriya Lifescience - General Updates

    2 Sep 2025, 2:25PM Enclosed herewith is the Letter under Regulation 36 (1) of SEBI (LODR)Regulations, 2015, dispatched by the Company to the Shareholders whose email ids

  • Supriya Lifescience - Business Responsibility and Sustainability Reporting (BRSR)

    1 Sep 2025, 7:28PM Business Responsibility and Sustainability Report of the Company forming part of Annual Report for FY 2024-25 is enclosed herewith.

  • Supriya Lifescience - Reg. 34 (1) Annual Report.

    1 Sep 2025, 7:18PM Annual Report of the Company for FY 2024-25 is enclosed herewith.

  • Supriya Lifescience - Notice Of 17Th Annual General Meeting Of Members Of The Company Scheduled To Be Held On Wednesday, Sept

    1 Sep 2025, 7:06PM Enclosed herewith is the Notice convening the 17th Annual General Meeting of Members of the Company scheduled to be held on Wednesday, September 24, 2

  • Supriya Lifescience - Shareholders meeting

    1 Sep 2025, 7:02PM Supriya Lifescience Limited has informed the Exchange regarding Notice of 17th Annual General Meeting to be held on September 24, 2025 at 3.00 pm. thr

  • Supriya Lifescience - Copy of Newspaper Publication

    1 Sep 2025, 1:32PM Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    19 Aug 2025, 2:52PM Supriya Lifescience Limited has informed the Exchange about Transcript

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    19 Aug 2025, 2:53PM Please find Transcript for the Earnings Call held on August 14, 2025.

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    14 Aug 2025, 4:43PM Supriya Lifescience Limited has informed the Exchange about Link of Recording

  • Supriya Lifescience - Copy of Newspaper Publication

    14 Aug 2025, 4:37PM Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication for the Unaudited Financial Results for the quarter ended Ju

  • Supriya Lifescience - Press Release

    14 Aug 2025, 3:53PM Supriya Lifescience Limited has informed the Exchange regarding a press release dated August 14, 2025, titled ""Press Release for the Unaudited Financ

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    14 Aug 2025, 4:44PM Please find attached herewith Audio Recording of the Earnings Call held today on August 14, 2025

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    14 Aug 2025, 3:54PM Press Release for the Unaudited Financial Results for the quarter ended June 30, 2025.

  • Supriya Lifescience - Investor Presentation

    13 Aug 2025, 6:28PM Supriya Lifescience Limited has informed the Exchange about Investor Presentation

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Investor Presentation

    13 Aug 2025, 6:28PM Investor Presentation for the quarter ended June 30, 2025

  • Supriya Lifescience - Amendment In Policy/Code Of The Company

    13 Aug 2025, 6:14PM The Company at its meeting held on August 13, 2025 has approved revised policy/code of the Company.

  • Supriya Lifescience - General Updates

    13 Aug 2025, 6:12PM Supriya Lifescience Limited has informed the Exchange about General Updates on amendment of Policies/code.

  • Supriya Lifescience Q1 net profit down 22.07% at Rs 34.79 cr

    13 Aug 2025, 6:10PM The company reported standalone net profit of Rs 34.79 crore for the quarter ended June 30, 2025 as compared to Rs 44.64 crore in the same period last

  • Supriya Lifescience - Unaudited Financial Result For The Quarter Ended On June 30, 2025

    13 Aug 2025, 6:01PM Unaudited Financial Results for the quarter ended June 30, 2025.\r\n\r\nKindly take the same on record.

  • Supriya Lifescience - Outcome of Board Meeting

    13 Aug 2025, 6:00PM Supriya Lifescience Limited has submitted to the Exchange, the Unaudited financial results for the quarter ended June 30, 2025.

  • Supriya Lifescience - Outcome of Board Meeting

    13 Aug 2025, 5:48PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directo

  • Supriya Lifescience - Board Meeting Outcome for Outcome Of The Board Meeting Held On August 13, 2025

    13 Aug 2025, 5:49PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directo

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    7 Aug 2025, 5:45PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call wil

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Aug 2025, 5:45PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended On June 30, 2025

    6 Aug 2025, 7:29PM Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider

  • Supriya Lifescience - Updates

    23 Jul 2025, 5:34PM Company has provided clarification regarding Demat requests received erroneously from shareholders of Supriya Pharmaceuticals Limited which is not rel

  • Supriya Lifescience - Clarification Regarding Shareholder Demat Requests

    23 Jul 2025, 5:34PM Company has provided Clarification regarding Demat requests received erroneously from Shareholders of Supriya Pharmaceuticals Limited which is not rel

  • Supriya Lifescience has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025

    19 Jul 2025, 5:30PM As of June 2025, 68.30% is owned by Indian Promoters and 31.70% by Public. <p align=justify> Institutional holds 11.64% (Insurance Companies 2.33%) an

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    18 Jul 2025, 5:20PM Pursuant to relevant provisions of the SEBI (LODR) Regulations, 2015, we would like to inform you that the officials of our Company will be interactin

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    18 Jul 2025, 5:20PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Jul 2025, 5:20PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    17 Jul 2025, 5:19PM Pursuant to relevant provisions of the SEBI (LODR) Regulations, 2015, we would like to inform you that the officials of our Company will be interactin

  • Supriya Lifescience - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    11 Jul 2025, 10:39AM Please find enclosed herewith duly signed certificate issued by MUFG Intime India Private Limited, our RTA, confirming compliance under Regulation 74(

  • Supriya Lifescience - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    11 Jul 2025, 10:34AM Supriya Lifescience Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Supriya Lifescience - Reply to Clarification- Financial results

    8 Jul 2025, 4:41PM The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Li

  • Supriya Lifescience - Disclosure under SEBI Takeover Regulations

    3 Jul 2025, 11:04PM Satish waman Waghÿhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial

  • Supriya Lifescience - General Updates

    1 Jul 2025, 4:48PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III and SEBI Master

  • Supriya Lifescience - Trading Window-XBRL

    27 Jun 2025, 5:15PM Supriya Lifescience Limited has informed the Exchange about Closure of Trading Window

  • Supriya Lifescience - Trading Window

    27 Jun 2025, 4:53PM Supriya Lifescience Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulatio

  • Supriya Lifescience - Clarification - Financial Results

    26 Jun 2025, 1:28PM The Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Li

  • Supriya Lifescience - Updates

    17 Jun 2025, 5:32PM Supriya Lifescience Limited has informed the Exchange regarding 'Email Communication To Shareholders Regarding Dividend Taxation Provisions'.

  • Supriya Lifescience - Email Communication To Shareholders Regarding Dividend Taxation Provisions

    17 Jun 2025, 5:32PM Email communication to shareholders regarding taxation provisions.

  • Supriya Life

    29 Sep 2022 , 11:11AM The company gets European drug body's approval for antihistamine drug. Diphenhydramine Hydrochloride is an antihistamine that reduces the effects of natural chemical histamine in the body. It is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching, and other cold or allergy symptoms – Positive read through for the stock.

  • Supriya Life gets European drug body's approval for antihistamine drug

    29 Sep 2022 , 9:41AM EDQM grants Certification of Suitability for Diphenhydramine Hydrochloride, API in AntiHistamine therapy
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Supriya Lifescience Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 996.76 815.368 716.083 636.983 335.993
Liabilities 996.76 815.368 716.083 636.983 335.993
Equity 16.097 16.097 16.097 16.097 14.637
Gross Profit 260.796 172.976 128.897 213.984 167.295
Net Profit 187.958 119.114 89.857 151.81 123.593
Cash From Operating Activities 164.676 113.307 66.187 48.801 78.905
NPM(%) 26.98 20.88 19.49 28.64 32.07
Revenue 696.485 570.37 460.938 530.049 385.366
Expenses 435.689 397.394 332.041 316.065 218.071
ROE(%) 20.74 13.14 9.91 16.75 13.64

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
04 Sep 2025 1 50 0 729.7
20 Sep 2024 0.8 40 0 363.1
15 Sep 2023 0.6 30 0 256.65
01 Sep 2022 0.6 30 0 378.15

Peers

Other companies within the same industry or sector that are comparable to Supriya Lifescience Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.00 0.77 73.44 374.02 301.39 0.62
Lotus Eye Hospital and Institute Ltd 120.00 -1.15 387.10 1362.89 3.55 0.00
Vaishali Pharma Ltd 12.09 0.33 403.00 702.48 3.13 0.00
Astec Lifesciences Ltd 855.00 0.30 0.00 1285.23 -604.77 0.00

Company Info

The Company was incorporated as `Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.Major events and milestones of the Company :2008- Incorporation of the Company upon its conversion from a partnership firm to a public limited company2009- Started production of Ketamine Hydrochloride2010- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate2011- IDL granted for Chlorphenamine Maleate2013- COFEPRIS and KFDA approval granted2014- USFDA approval granted- IDL granted for Brompheniramine Maleate2015- EUGMP and EDQM approval granted2017- CEP (Certificate of Sustainability) granted for Pheniramine Maleate- Second time USFDA approval granted2018- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride2020- Third time USFDA approval2021- CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate- NMPA approval granted- Health Canada approval 2022 -Supriya Lifescience Limited has informed the Exchange regarding 'Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd'. 2024 -"Supriya Lifescience Ltd Inaugurates State-of-the-Art Module E Production Block at Lote Parshuram, Maharashtra". --Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site.

The Company was incorporated as `Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.Major events and milestones of the Company :2008- Incorporation of the Company upon its conversion from a partnership firm to a public limited company2009- Started production of Ketamine Hydrochloride2010- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate2011- IDL granted for Chlorphenamine Maleate2013- COFEPRIS and KFDA approval granted2014- USFDA approval granted- IDL granted for Brompheniramine Maleate2015- EUGMP and EDQM approval granted2017- CEP (Certificate of Sustainability) granted for Pheniramine Maleate- Second time USFDA approval granted2018- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride2020- Third time USFDA approval2021- CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate- NMPA approval granted- Health Canada approval 2022 -Supriya Lifescience Limited has informed the Exchange regarding 'Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd'. 2024 -"Supriya Lifescience Ltd Inaugurates State-of-the-Art Module E Production Block at Lote Parshuram, Maharashtra". --Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site.

Read More

Parent Organisation

Supriya Lifescience Ltd.

Founded

26/03/2008

Managing Director

NSE Symbol

SUPRIYAEQ

FAQ

The current price of Supriya Lifescience Ltd is ₹ 656.75.

The 52-week high for Supriya Lifescience Ltd is ₹ 670.00 and the 52-week low is ₹ 655.50.

The market capitalization of Supriya Lifescience Ltd is currently ₹ 5285.71. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Supriya Lifescience Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Supriya Lifescience Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Supriya Lifescience Ltd shares.

The CEO of Supriya Lifescience Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT